Offshore Medical Transcription - Totalmed Transcription Offers Medical Transcription Outsourcing Services from India to get better outsource result for your outsourcing medical transcription contact us online at totalmedtranscription.net.
MD Consultants of America is a leading Healthcare outsourcing solutions company based in Peoria, IL. Our in-depth understanding of the Healthcare industry enables us to provide innovative end-to-end Business Process Outsourcing (BPO) solutions to our clients.
MD Consultants of America is a leading Healthcare outsourcing solutions company based in Peoria, IL. Our in-depth understanding of the Healthcare industry enables us to provide innovative end-to-end Business Process Outsourcing (BPO) solutions to our clients.
MD Consultants of America is a leading Healthcare outsourcing solutions company based in Peoria, IL. Our in-depth understanding of the Healthcare industry enables us to provide innovative end-to-end Business Process Outsourcing (BPO) solutions to our clients.
Offshore Medical Transcription - Totalmed Transcription Offers Medical Transcription Services from India to get better outsource result for your offshore medical transcription, contact us online at totalmedtranscription.net.
Skelmersdale-based online pharmacy Chemist4U has secured a £12 million investment from Pitalia Capital, an equity investment company led by Anil Pitalia.
Chemist4U is part of JCCO Healthcare, which also houses the weight management platform myBMI. Anil Pitalia is a health enthusiast, who heads SpaMedica, a company
providing cataract surgery to the NHS.
This investment will propel the group's expansion, with John Davies, Managing Partner of Pitalia Capital, joining the board, the company said. Moreover, it will
facilitate the extension of services by myBMI in the realm of weight management.
"Our goal is for Chemist4U to emerge as one of the largest NHS dispensing facilities in the country, while also providing vital support to our partners through our
rapidly expanding outsourced dispensing services division," said said James O'Loan, Chief Executive Officer of both Chemist4U and myBMI, who joined Chemist4U as a
superintendent pharmacist in 2012 before becoming CEO in 2018.
Meanwhile, Anil Pitalia, Head of Pitalia Capital based in Bolton, cited the compelling growth potential as the driving force behind his investment in Chemist4U's
next-day medicine delivery service.
Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a
non-executive board director.
With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical
company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business.
During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to
sustainable growth and profitability.
The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are
critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful
acquisition by Perrigo Company plc."
David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's
growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.
Talk of hub and spoke models has been rumbling on for as long as I can remember. The topic has once again hit the headlines as the government announced a
fresh consultation for its proposed changes, calling on all interested parties to submit their views by 8th June.
The argument for hub and spoke is to allow independents to have the same level playing field as the larger groups who have been operating this model for some time.
The government also sees significant efficiency gains in centralisation, arguing this will free pharmacists time away from dispensing to focus on clinical services.
The latest consultation advocates two models being created. In the first model, the dispensed medication is sent back to the spoke. In the second model, the completed
medication can be sent out directly to the patient.
The latter is a new concept which could open up new opportunities in how services are delivered. Pharmacies could effectively outsource the entire dispensing and
delivery to housebound patients and care homes allowing pharmacies to take on new business without having to worry about logistics and geography.
Viveca Biomed has launched an innovative and clinically-proven bladder support device that offers women immediate relief from stress urinary incontinence (SUI)
and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins.
The product, named 'Contrelle Activgard', has already recorded millions of sales in Scandinavia over a decade.
The company behind the UK launch is female healthcare business Viveca Biomed, founded in 2019 by Andrew Tasker who has spent 30+ years in senior roles within the OTC
and pharma industry.
Contrelle is manufactured, packed and distributed in the UK at Viveca Biomed's factory near Newcastle, with no outsourcing, and thus offering the best possible
continuity of supply.
Ahead of the launch, the company commissioned a large consumer lifestyle survey with 500 women over 40 years of age who experience bladder leaks, to reveal the extent
of its detrimental impact.
Contrelle Activgard is a safe, discrete, easy-to-use and highly effective, single-use vaginal device, designed to immediately prevent SUI rather than just deal
with the leakage.
Various state governments are looking at outsourcing MRI services in their district hospitals to private players which is enabling high-quality low cost scanning for patients visiting government hospitals, without any investment whatsoever from the government The growth of MRI as a diagnostic modality in India was limited initially by two factors.